Predictive Factors of Response to Phase II Cardiac Rehabilitation in Heart Failure With Reduced Ejection Fraction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

62 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-11-25

Study Completion Date

2027-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Exercise intolerance, measured as peak oxygen consumption (VO₂peak) during exercise in patients with heart failure with reduced ejection fraction (HFrEF). Change in VO₂peak (ΔVO₂peak), which serves as a prognostic marker for HFrEF engaged in exercise based cardiac rehabilitation program (ExCR). Responders to ExCR generally show improved cardiac function but some patients with HFrEF do not respond to ExCR. VO₂peak depends on three major components of oxygen transport: Pulmonary (lungs), circulatory (heart and vessels) and skeletal muscle (oxygen utilization) functions. These physiological responses to ExCR may be influenced by epigenetic regulation, specifically the expression of circulating microRNAs (c-miRNAs).

Linking non-invasive measurements and epigenetic markers could 1) identify which component of the oxygen transport chain is most impaired and 2) allow personalized interventions to maximize VO₂peak improvements.

The primary objective of this stidy is to assess the association between changes in VO₂peak during exercise training and circulating microRNA expression (miR-146a, miR-191, miR-23a, miR-140, miR-1, miR-21, miR-133a, miR-17-5p, miR-3200-3p).

The secondary objective is to examine the relationship between pulmonary, cardiovascular, and neuromuscular adaptations to exercise and circulating microRNA expression.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Key Takeaways VO₂peak is a clinically relevant, prognostic measure in HFrEF. .ExCR benefits are heterogeneous, partly due to variable cardiac and muscular adaptations. c-miRNAs may mediate or indicate the molecular response to ExCR. c-miRNAs may Enhance pulmonary, cardiac, or muscular adaptations → improved VO₂peak, or, if maladaptive, contribute to fatigue → explaining non-response.

Goal Connect ΔVO₂peak with cellular precursors of adaptation, providing a mechanistic understanding of CR responses.

Method 62 patients with HFrEF will be engaged in a this prospective, single-center cohort follow-up study with a prognostic aim and minimal risk to human participants.

Peak values of oxygen uptake, cardiac hemodynamics, cerebral and muscle oxygenation, non-coding RNA will be measured before and after Exercise based cardiac rehabilitation during a cardiopulmonary exercise testing. All the patients will perform a force - velocity test in order to prescribe an individualized resistance training program.

Originality of study: Combines non-invasive physiological measurements during exercise and biomarker (c-miRNA) analysis before and after ExCR.

Scientific and Clinical Significance

Linking non-invasive measurements and epigenetic markers could:

1. Identify which component of the oxygen transport chain is most impaired.
2. Combining physiological and molecular assessments could guide tailored rehabilitation strategies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HFrEF - Heart Failure With Reduced Ejection Fraction Cardiac Rehabilitation Exercise Training Exercise Adaptations Exercise Intolerance Exercise Intervention

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Heart failure with reduced ejection fraction \< 40%
* NYHA functional class ≥ II
* Clinically stable for at least 6 weeks
* On optimized medical therapy for at least 6 weeks
* Prescription for phase II cardiac rehabilitation
* BMI between 20-30 kg·m-²
* Physical activity level: sedentary or physically active but untrained
* Signed informed consent to participate in the study
* Affiliation to the French national health insurance system

Exclusion Criteria

* Contraindication to regular adapted physical activity
* Uncontrolled arterial hypertension
* Secondary respiratory disease such as emphysema or chronic obstructive pulmonary disease (COPD)
* Secondary cardiovascular disease
* Individuals under legal protection or deprived of liberty
* Pregnant or breastfeeding women

Minimum Eligible Age

40 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pierre-Marie Leprêtre, Professor

Role: STUDY_DIRECTOR

Université de Rouen Normandie, UFR-STAPS

Francesco Orlando, MD

Role: PRINCIPAL_INVESTIGATOR

Centre Hospitalier de Corbie

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital center of Corbie

Corbie, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Pierre-Marie Leprêtre, professor

Role: CONTACT

[email protected]

+33235148113

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Pierre-Marie Leprêtre, PhD

Role: primary